Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Vaccines Market Worth $50.42 Billion by 2023 | ||
| By: PR Newswire Association LLC. - 14 Aug 2018 | Back to overview list |
|
PUNE, India, August 14, 2018 /PRNewswire/ -- According to a new market research report "Vaccines Market by Technology (Live, Toxoid, Recombinant), Disease (Pneumococcal, Influenza, DTP, HPV, Hepatitis, Meningococcal, Rotavirus, Polio, MMR, Varicella, Dengue), Route (IM/SC, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2023", published by MarketsandMarkets™, the market is expected to reach USD 50.42 billion by 2023 from USD 36.45 billion in 2018, at a CAGR of 6.7%. (Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg ) Browse 93 market data Tables and 46 Figures spread through 184 Pages and in-depth TOC on "Vaccines Market" https://www.marketsandmarkets.com/Market-Reports/vaccine-technologies-market-1155.html Early buyers will receive 10% customization on this report The growth of the market is attributed to the rising prevalence of diseases, increasing government and nongovernment funding for vaccine development, and increasing companies' initiatives to enhance R&D. Conjugate vaccines to dominate the market in 2018 Based on technology, the Vaccines Market is segmented into conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. In 2018, the conjugate segment is expected to account for the largest share of the Vaccines Market. The growth in this market is mainly driven by increasing investments by the government of developing countries and rising prevalence of infectious diseases. Based on disease indication, the meningococcal segment is projected to grow at the highest CAGR during the forecast period. By disease indication, the Vaccines Market is segmented into pneumococcal disease, influenza, DTP, hepatitis, human papillomavirus (HPV), rotavirus, meningococcal disease, MMR (measles, mumps, and rubella), varicella, polio, herpes zoster, dengue, and other disease indications. The meningococcal segment is expected to register the highest rate during the forecast period. The growth in this segment can primarily be attributed to the increasing government investments in meningococcal vaccination programs and high prevalence of meningococcal disease. Ask for PDF Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=1155 North America to dominate the Vaccines Market In 2018, North America is expected to dominate the market. The large share of this geographical segment is attributed to factors such as increasing investments by government organizations and companies to promote immunization as well as develop new vaccines. Europe is expected to hold the second largest share of this market. Factors such as availability of funding and venture capital investments for the development of new vaccines and increasing government initiatives are expected to drive market growth in this region. The Vaccines Market is highly competitive with the presence of several small and big players. Some of the players in the Vaccines Market are GlaxoSmithKline plc (UK), Pfizer, Inc. (US), Merck & Co., Inc. (US), Sanofi Pasteur SA (France), CSL Limited (Australia), Emergent BioSolutions, Inc. (US), Johnson & Johnson (US), MedImmune, LLC (US), Astellas Pharma Inc. (Japan), Serum Institute of India (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), and Daiichi Sankyo Company, Limited (Japan). Know more about the Vaccines Market: https://www.marketsandmarkets.com/Market-Reports/vaccine-technologies-market-1155.html https://www.marketsandmarkets.com/Market-Reports/vaccine-technologies-market-1155.html About MarketsandMarkets™ MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Contact: Research Insight: https://www.marketsandmarkets.com/ResearchInsight/vaccine-technologies-market.asp Connect with us on LinkedIn: http://www.linkedin.com/company/marketsandmarkets SOURCE MarketsandMarkets 
|
||
|
|
||
 | Back to overview list | |
